Jacobs Levy Equity Management
TCRR

Jacobs Levy Equity Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Jacobs Levy Equity Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-83,360
Closed -$150K – 1070
2022
Q3 		$150K Buy
+83,360
New +$242K ﹤0.01% 948
2022
Q1 		– Sell
-204,290
Closed -$952K – 1111
2021
Q4 		$952K Buy
+204,290
New +$1.28M 0.01% 745
2020
Q4 		– Sell
-35,768
Closed -$727K – 1116
2020
Q3 		$727K Sell
35,768
-6,105
-15% -$107K 0.01% 719
2020
Q2 		$643K Buy
+41,873
New +$483K 0.01% 746

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jacobs Levy Equity Management's TCRR Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 83,360 shares — an estimated $150K sold.

Jacobs Levy Equity Management first reported a position in TCRR in Q2 2020 and held it in 4 quarters. The position peaked at $952K in Q4 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 83,360 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $150K.
  • Jacobs Levy Equity Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Jacobs Levy Equity Management's TCR2 Therapeutics Inc. Common Stock position peaked at $952K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.